126 related articles for article (PubMed ID: 37598940)
1. Immunomodulatory effects of tenofovir disoproxil fumarate and entecavir in treating HBV infection.
Yu X; Long J; Xie Y; Zhang J; Su Z
J Hepatol; 2024 Mar; 80(3):e123-e125. PubMed ID: 37598940
[No Abstract] [Full Text] [Related]
2. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.
Suzuki K; Suda G; Yamamoto Y; Furuya K; Baba M; Nakamura A; Miyoshi H; Kimura M; Maehara O; Yamada R; Kitagataya T; Yamamoto K; Shigesawa T; Nakamura A; Ohara M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Sakamoto N;
J Gastroenterol; 2021 Feb; 56(2):168-180. PubMed ID: 33211179
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Buti M; Gane E; Seto WK; Chan HL; Chuang WL; Stepanova T; Hui AJ; Lim YS; Mehta R; Janssen HL; Acharya SK; Flaherty JF; Massetto B; Cathcart AL; Kim K; Gaggar A; Subramanian GM; McHutchison JG; Pan CQ; Brunetto M; Izumi N; Marcellin P;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):196-206. PubMed ID: 28404092
[TBL] [Abstract][Full Text] [Related]
5. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin-free strategy to prevent HBV mother-to-child transmission in Cambodia (TA-PROHM): a single-arm, multicentre, phase 4 trial.
Segeral O; Dim B; Durier C; Nhoueng S; Chhim K; Sovann S; Yom S; Vong C; Yin S; Ros B; Ky V; Pech S; Nem B; Hout K; Guillebaud J; Ear E; Caroupaye-Caroupin L; Rekacewicz C; Fernandez L; Laurent D; Yay C; Kim R; Meyer L; Chhun S;
Lancet Infect Dis; 2022 Aug; 22(8):1181-1190. PubMed ID: 35643089
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.
Chan HL; Fung S; Seto WK; Chuang WL; Chen CY; Kim HJ; Hui AJ; Janssen HL; Chowdhury A; Tsang TY; Mehta R; Gane E; Flaherty JF; Massetto B; Gaggar A; Kitrinos KM; Lin L; Subramanian GM; McHutchison JG; Lim YS; Acharya SK; Agarwal K;
Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):185-195. PubMed ID: 28404091
[TBL] [Abstract][Full Text] [Related]
8. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
Lampertico P; Buti M; Fung S; Ahn SH; Chuang WL; Tak WY; Ramji A; Chen CY; Tam E; Bae H; Ma X; Flaherty JF; Gaggar A; Lau A; Liu Y; Wu G; Suri V; Tan SK; Subramanian GM; Trinh H; Yoon SK; Agarwal K; Lim YS; Chan HLY
Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
[TBL] [Abstract][Full Text] [Related]
9. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection.
Li P; Wang Y; Yu J; Yu J; Tao Q; Zhang J; Lau WY; Zhou W; Huang G
JAMA Netw Open; 2023 Oct; 6(10):e2340353. PubMed ID: 37906195
[TBL] [Abstract][Full Text] [Related]
11. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial.
Avihingsanon A; Lu H; Leong CL; Hung CC; Koenig E; Kiertiburanakul S; Lee MP; Supparatpinyo K; Zhang F; Rahman S; D'Antoni ML; Wang H; Hindman JT; Martin H; Baeten JM; Li T;
Lancet HIV; 2023 Oct; 10(10):e640-e652. PubMed ID: 37494942
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL; Lu Y; Yoshida K; Zhao T; Boucheron P; van Holten J; Chou R; Bulterys M; Shimakawa Y
Lancet Infect Dis; 2021 Jan; 21(1):70-84. PubMed ID: 32805200
[TBL] [Abstract][Full Text] [Related]
14. Effects of Long-Term Tenofovir and Entecavir Treatment on Bone Mineral Density in Patients with Chronic Hepatitis B.
Kahraman R; Şahin A; Öztürk O; Çalhan T; Sayar S; Kanat E; Doğanay L; Özdil K
Turk J Gastroenterol; 2022 Jan; 33(1):35-43. PubMed ID: 35040786
[TBL] [Abstract][Full Text] [Related]
15. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Rago A; Lichtner M; Mecarocci S; Marocco R; Cenfra N; Belvisi V; Del Borgo C; Cimino G; Mastroianni CM
Antivir Ther; 2010; 15(6):929-32. PubMed ID: 20834107
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir does not induce renal dysfunction compared to entecavir in post-liver-transplant hepatitis B virus patients.
Kim SJ; Rhu J; Lee SH; Kim JM; Choi GS; Kim K; Joh JW
Ann Surg Treat Res; 2020 Sep; 99(3):180-187. PubMed ID: 32908850
[TBL] [Abstract][Full Text] [Related]
17. Does Hepatic Steatosis Influence the Virological Response with Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir Disoproxil Fumarate?
Atalay R; Sayar S; Ayrancı FG; Çakmak Ş; Tanboğa İH; Doğanay L; Özdil K
Turk J Gastroenterol; 2022 Jul; 33(7):587-595. PubMed ID: 35879916
[TBL] [Abstract][Full Text] [Related]
18. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial.
Hsu YC; Chen CY; Chang IW; Chang CY; Wu CY; Lee TY; Wu MS; Bair MJ; Chen JJ; Chen CC; Tseng CH; Tai CM; Huang YT; Ku WH; Mo LR; Lin JT
Lancet Infect Dis; 2021 Jun; 21(6):823-833. PubMed ID: 33524314
[TBL] [Abstract][Full Text] [Related]
19. A pregnant woman with acute hepatitis B in whom vertical transmission was prevented by tenofovir disoproxil fumarate.
Tooyama M; Tamori A; Nakano A; Hai H; Thuy le TT; Enomoto M; Kawada N
Clin J Gastroenterol; 2013 Apr; 6(2):173-6. PubMed ID: 26181458
[TBL] [Abstract][Full Text] [Related]
20. Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.
Bukkems VE; Smolders EJ; Jourdain G; Burger DM; Colbers AP; Cressey TR;
J Clin Pharmacol; 2021 Mar; 61(3):388-393. PubMed ID: 32960984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
